| Abstract | Since its introduction into clinical trials in the mid 1970's and its widespread use since the early 1980's, isotretinoin has proved a very effective therapy for severe and persistent acne. Initially only used for severe cystic acne, its use has been gradually extended for those with significant but milder disease that has been persistent despite the use of conventional topical and oral therapies. The current document expresses the view of the BAD on the use of isotretinoin on the basis of current knowledge. It does not discuss the indications for use of isotretinoin that are the subject of a BAD Guideline which is currently in production, but considers the precautions necessary before and during therapy. |